287 related articles for article (PubMed ID: 12244613)
1. The HMG Co-A reductase inhibitors ('statins') and myotoxic effects.
S Afr Med J; 2002 Aug; 92(8):596-7. PubMed ID: 12244613
[No Abstract] [Full Text] [Related]
2. [Statin therapy and muscle disorders].
Abel T; Fehér J
Orv Hetil; 2009 Feb; 150(6):261-3. PubMed ID: 19179258
[No Abstract] [Full Text] [Related]
3. Risk factors for rhabdomyolysis with simvastatin and atorvastatin.
Golomb B; Evans M
Drug Saf; 2006; 29(12):1191; author reply 1191-2. PubMed ID: 17147465
[No Abstract] [Full Text] [Related]
4. Muscular adverse effects of statins.
Prescrire Int; 2003 Feb; 12(63):21. PubMed ID: 12602397
[No Abstract] [Full Text] [Related]
5. Safety and efficacy of atorvastatin in heart transplant recipients.
Patel DN; Pagani FD; Koelling TM; Dyke DB; Baliga RR; Cody RJ; Lake KD; Aaronson KD
J Heart Lung Transplant; 2002 Feb; 21(2):204-10. PubMed ID: 11834348
[TBL] [Abstract][Full Text] [Related]
6. Statin-associated rhabdomyolysis: is there a dose-response relationship?
Holbrook A; Wright M; Sung M; Ribic C; Baker S
Can J Cardiol; 2011; 27(2):146-51. PubMed ID: 21459261
[TBL] [Abstract][Full Text] [Related]
7. A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan.
Saito M; Hirata-Koizumi M; Urano T; Miyake S; Hasegawa R
J Clin Pharm Ther; 2005 Feb; 30(1):21-37. PubMed ID: 15659001
[TBL] [Abstract][Full Text] [Related]
8. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs.
Roberts WC
Am J Cardiol; 1997 Jul; 80(1):106-7. PubMed ID: 9205036
[No Abstract] [Full Text] [Related]
9. [Statins after drug discontinuation are usually well tolerated].
Steurer J
Praxis (Bern 1994); 2013 Jun; 102(13):813. PubMed ID: 23773943
[No Abstract] [Full Text] [Related]
10. Statin-induced myositis migrans.
Sinzinger H
Wien Klin Wochenschr; 2002 Nov; 114(21-22):943-4. PubMed ID: 12528328
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.
Rätz Bravo AE; Tchambaz L; Krähenbühl-Melcher A; Hess L; Schlienger RG; Krähenbühl S
Drug Saf; 2005; 28(3):263-75. PubMed ID: 15733030
[TBL] [Abstract][Full Text] [Related]
12. Statins alone are ineffective in cerebral malaria but potentiate artesunate.
Bienvenu AL; Picot S
Antimicrob Agents Chemother; 2008 Nov; 52(11):4203-4. PubMed ID: 18779350
[No Abstract] [Full Text] [Related]
13. Risk of incident diabetes among patients treated with statins: population based study.
Carter AA; Gomes T; Camacho X; Juurlink DN; Shah BR; Mamdani MM
BMJ; 2013 May; 346():f2610. PubMed ID: 23704171
[TBL] [Abstract][Full Text] [Related]
14. Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes.
Ramachandran S; Saraf S; Shetty C; Capps N; Bailey C
Ann Clin Biochem; 2011 Jan; 48(Pt 1):75-8. PubMed ID: 21115572
[TBL] [Abstract][Full Text] [Related]
15. [High dose of simvastatin to minimize the risk of myopathy?].
Frey O
Med Monatsschr Pharm; 2010 Sep; 33(9):354-5. PubMed ID: 21192445
[No Abstract] [Full Text] [Related]
16. Statin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro.
Skottheim IB; Gedde-Dahl A; Hejazifar S; Hoel K; Asberg A
Eur J Pharm Sci; 2008 Apr; 33(4-5):317-25. PubMed ID: 18294823
[TBL] [Abstract][Full Text] [Related]
17. Fluvastatin, rhabdomyolysis, and myotoxicity.
Murinson BB; Maragakis NJ; Jacobson TA
Mayo Clin Proc; 2008 Nov; 83(11):1296; author reply 1297. PubMed ID: 18990330
[No Abstract] [Full Text] [Related]
18. Managed care trends in statin usage.
Bazalo GR
Manag Care; 2001 Oct; 10(10):48-50, 53-9. PubMed ID: 11688111
[TBL] [Abstract][Full Text] [Related]
19. Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors.
Molden E; Skovlund E; Braathen P
Drug Saf; 2008; 31(7):587-96. PubMed ID: 18558792
[TBL] [Abstract][Full Text] [Related]
20. Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors.
Cromwell WC; Ziajka PE
Am J Cardiol; 2000 Nov; 86(10):1123-7. PubMed ID: 11074211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
